Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 371

1.

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.

Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ.

Cell Rep. 2019 Oct 1;29(1):118-134.e8. doi: 10.1016/j.celrep.2019.08.090.

2.

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.

Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, Marco E, Chen T, Gray NS, Wong KK, Orkin SH, Yuan GC, Young RA, George RE.

Nature. 2019 Aug;572(7771):676-680. doi: 10.1038/s41586-019-1472-0. Epub 2019 Aug 7.

PMID:
31391581
3.

Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations.

de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL.

Nat Commun. 2019 Aug 1;10(1):3468. doi: 10.1038/s41467-019-11429-w.

4.

Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice.

Tang X, Drotar J, Li K, Clairmont CD, Brumm AS, Sullins AJ, Wu H, Liu XS, Wang J, Gray NS, Sur M, Jaenisch R.

Sci Transl Med. 2019 Jul 31;11(503). pii: eaau0164. doi: 10.1126/scitranslmed.aau0164.

PMID:
31366578
5.

The Triarchic Model of Psychopathy and Antisocial Behavior: Results From an Offender Population With Personality Disorder.

Gray NS, Blumenthal S, Shuker R, Wood H, Fonagy P, Snowden RJ.

J Interpers Violence. 2019 Jun 13:886260519853404. doi: 10.1177/0886260519853404. [Epub ahead of print]

PMID:
31189393
6.

Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.

Ferguson FM, Doctor ZM, Ficarro SB, Marto JA, Kim ND, Sim T, Gray NS.

Bioorg Med Chem Lett. 2019 Aug 1;29(15):1985-1993. doi: 10.1016/j.bmcl.2019.05.024. Epub 2019 May 23.

PMID:
31175010
7.

Quinoline and thiazolopyridine allosteric inhibitors of MALT1.

Scott DA, Hatcher JM, Liu H, Fu M, Du G, Fontán L, Us I, Casalena G, Qiao Q, Wu H, Melnick A, Gray NS.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1694-1698. doi: 10.1016/j.bmcl.2019.05.040. Epub 2019 May 20.

PMID:
31129051
8.

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.

To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA.

Cancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15.

PMID:
31092401
9.

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J.

Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005.

PMID:
31085176
10.

JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells.

Du L, Anderson A, Nguyen K, Ojeda SS, Ortiz-Rivera I, Nguyen TN, Zhang T, Kaoud TS, Gray NS, Dalby KN, Tsai KY.

ACS Chem Biol. 2019 Jul 19;14(7):1426-1435. doi: 10.1021/acschembio.9b00083. Epub 2019 May 17.

PMID:
31063355
11.

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.

Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, Gray NS, Young RA, Geyer M, Gerber SA, George RE.

Nat Commun. 2019 Apr 15;10(1):1757. doi: 10.1038/s41467-019-09703-y.

12.

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.

Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS.

Cell Chem Biol. 2019 Jun 20;26(6):818-829.e9. doi: 10.1016/j.chembiol.2019.02.021. Epub 2019 Apr 11.

PMID:
30982749
13.

Peptide-based covalent inhibitors of MALT1 paracaspase.

Hatcher JM, Du G, Fontán L, Us I, Qiao Q, Chennamadhavuni S, Shao J, Wu H, Melnick A, Gray NS, Scott DA.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1336-1339. doi: 10.1016/j.bmcl.2019.03.046. Epub 2019 Mar 29.

PMID:
30954428
14.

Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.

Ferguson FM, Doctor ZM, Ficarro SB, Browne CM, Marto JA, Johnson JL, Yaron TM, Cantley LC, Kim ND, Sim T, Berberich MJ, Kalocsay M, Sorger PK, Gray NS.

Cell Chem Biol. 2019 Jun 20;26(6):804-817.e12. doi: 10.1016/j.chembiol.2019.02.015. Epub 2019 Mar 28.

PMID:
30930164
15.

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.

Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D, Zhang T, Huang HT, Lucente DE, Dickerson BC, Mitchison TJ, Fischer ES, Gray NS, Haggarty SJ.

Elife. 2019 Mar 25;8. pii: e45457. doi: 10.7554/eLife.45457.

16.

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.

Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS.

Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10. doi: 10.1016/j.chembiol.2019.02.012. Epub 2019 Mar 21.

PMID:
30905681
17.

A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.

Rao S, Du G, Hafner M, Subramanian K, Sorger PK, Gray NS.

J Biol Chem. 2019 May 24;294(21):8664-8673. doi: 10.1074/jbc.RA118.006805. Epub 2019 Mar 11.

18.

Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors.

4° JOINT MEETING OF PATHOLOGY AND LABORATORY MEDICINE SIPMET–SIPMEL - SECOND JOINT MEETING IN COLLABORATION WITH ASIP–AMP–UEMS–WASPALM - 4° SIPMEL NATIONAL CONGRESS - 34° SIPMET NATIONAL CONGRESS - 4° CONGRESS OF PATHOLOGY AND LABORATORY MEDICINE, Tusa I, Cheloni G, Poteti M, Gozzini A, Deng X, Gray NS, Li S, Dello Sbarba P, Rovida E.

J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4 Suppl. 1):36. No abstract available.

PMID:
30810012
19.

Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.

Jiang B, Wang ES, Donovan KA, Liang Y, Fischer ES, Zhang T, Gray NS.

Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. doi: 10.1002/anie.201901336. Epub 2019 Mar 29.

PMID:
30802347
20.

Identification of small molecule inhibitors targeting the Zika virus envelope protein.

Pitts J, Hsia CY, Lian W, Wang J, Pfeil MP, Kwiatkowski N, Li Z, Jang J, Gray NS, Yang PL.

Antiviral Res. 2019 Apr;164:147-153. doi: 10.1016/j.antiviral.2019.02.008. Epub 2019 Feb 13.

PMID:
30771406

Supplemental Content

Support Center